Genscript Biotech Corporation (HKG:1548)
12.36
+0.51 (4.30%)
Apr 2, 2026, 4:08 PM HKT
Genscript Biotech Revenue
In the year 2025, Genscript Biotech had annual revenue of $959.53M USD with 61.40% growth. Genscript Biotech had revenue of $440.75M in the half year ending December 31, 2025.
Revenue
$959.53M
Revenue Growth
+61.40%
P/S Ratio
3.62
Revenue / Employee
$155.64K
Employees
6,165
Market Cap
27.03B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 959.53M | 365.04M | 61.40% |
| Dec 31, 2024 | 594.49M | 34.01M | 6.07% |
| Dec 31, 2023 | 560.48M | -65.22M | -10.42% |
| Dec 31, 2022 | 625.70M | 135.60M | 27.67% |
| Dec 31, 2021 | 490.10M | 99.25M | 25.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Henlius Biotech | 7.42B |
| Zai Lab | 3.58B |
| Shanghai Junshi Biosciences | 2.78B |
| InnoCare Pharma | 2.64B |
| Duality Biotherapeutics | 2.06B |
| Biocytogen Pharmaceuticals (Beijing) | 1.53B |
| Keymed Biosciences | 797.12M |
| Ascentage Pharma Group International | 638.89M |
Genscript Biotech News
- 20 days ago - GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth - PRNewsWire
- 20 days ago - Genscript Biotech Corp (GNNSF) Full Year 2025 Earnings Call Highlights: Record Revenue Growth ... - GuruFocus
- 20 days ago - Full Year 2025 Genscript Biotech Corp Earnings Call Transcript - GuruFocus
- 8 months ago - GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation - PRNewsWire
- 8 months ago - GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader - PRNewsWire
- 1 year ago - GenScript Biotech Corporation Reports FY 2024 Results - PRNewsWire
- 1 year ago - The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development - PRNewsWire
- 1 year ago - GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia - PRNewsWire